Opinion|Videos|January 13, 2025
Emerging Therapies: a look at the current data: APPLAUSE
Key Takeaways
- Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
- Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.
Advertisement
Episodes in this series
- In the phase 3 ALIGN trial (
NCT04573478 ), atrasentan demonstrated a 36% relative reduction in proteinuria with placebo after 36 weeks of treatment. What other data points would be relevant for clinicians?
Advertisement
Related to this article
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
Advertisement
Advertisement
Trending on HCPLive
1
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
2
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5